Leadership Overview
Teva has 10 executives leading key functions including finance, strategy, and marketing.
Driven by a commitment to improving global health outcomes, Teva develops, manufactures, and delivers a broad portfolio of medicines, advancing scientific research and expanding access to quality treatments.
Driven by a commitment to improving global health outcomes, Teva develops, manufactures, and delivers a broad portfolio of medicines, advancing scientific research and expanding access to quality treatments.
Leadership Roles at Teva
Marija Bubanja - Chief Financial Officer
Marija Bubanja, the Chief Financial Officer at Teva, directs the company's overall financial strategy and operations. This leadership position involves overseeing all fiscal activities, including financial planning, budgeting, and reporting, ensuring robust financial health and compliance across global markets. Bubanja's oversight extends to managing investment strategies and optimizing capital allocation to support Teva's mission of improving health outcomes. The Chief Financial Officer's role is critical in driving sustainable growth and profitability by analyzing market trends and financial performance. Marija Bubanja ensures that financial decisions align with the company's strategic objectives, supporting the development and delivery of a broad portfolio of medicines, from complex generics to innovative therapies. This executive function is vital for maintaining investor confidence and facilitating the company's expansion into new therapeutic areas and geographic regions, directly contributing to Teva's dedication to addressing unmet patient needs worldwide.
Luigi Tiravanti - Director, Finance & Chief Financial Officer
Luigi Tiravanti, the Director, Finance & Chief Financial Officer at Teva, manages critical financial functions that support the company's global biopharmaceutical operations. This role encompasses the strategic direction of financial planning and analysis, ensuring fiscal discipline and resource optimization across diverse business units. Tiravanti's responsibilities include overseeing financial reporting, compliance, and the implementation of financial controls that uphold Teva's commitment to quality and accessibility of medicines. The Director, Finance & Chief Financial Officer's influence extends to evaluating investment opportunities and managing financial risks, thereby safeguarding the company's assets and enhancing shareholder value. Luigi Tiravanti plays a key part in streamlining financial processes to support the delivery of Teva's broad portfolio, including complex generics and innovative therapies, thereby contributing to improved patient health outcomes globally. This executive function is essential for maintaining operational efficiency and driving strategic financial initiatives.
Alexander Joramsa - Chief Financial Officer (Asia Pacific, Japan)
Alexander Joramsa, the Chief Financial Officer (Asia Pacific, Japan) at Teva, spearheads financial strategy and operations for the critical Asia Pacific and Japan regions. This executive role involves directing all fiscal activities, including financial planning, budgeting, and reporting, tailored to the unique market dynamics of these territories. Joramsa's oversight ensures robust financial health and compliance, supporting Teva's mission to expand access to quality medicines across diverse patient populations. The Chief Financial Officer (Asia Pacific, Japan)'s responsibilities include analyzing regional market trends, optimizing capital allocation, and driving sustainable growth within these key markets. Alexander Joramsa's leadership is instrumental in navigating regulatory landscapes and fostering financial strategies that align with the company's global objectives, thereby enhancing Teva's presence and impact in the region. This function is vital for delivering Teva's broad portfolio of treatments effectively.
Craig Olson - Chief Financial Officer, Operations
Craig Olson, the Chief Financial Officer, Operations at Teva, directs the financial strategy and execution for the company's extensive manufacturing and supply chain operations. This critical role involves overseeing all aspects of operational finance, including cost management, capital expenditure planning, and financial performance analysis for Teva's global production facilities. Olson's responsibilities extend to ensuring financial efficiency and optimizing resource allocation to support the reliable delivery of a broad portfolio of medicines. The Chief Financial Officer, Operations's influence is crucial in driving operational excellence and cost-effectiveness, directly impacting Teva's ability to provide affordable and accessible treatments worldwide. Craig Olson's financial leadership ensures that operational investments align with strategic goals, supporting Teva's commitment to advancing scientific research and improving patient health outcomes. This executive function is vital for maintaining the integrity and efficiency of Teva's manufacturing capabilities.
Dov Primovitch - Chief Financial Officer (Israel)
Dov Primovitch, the Chief Financial Officer (Israel) at Teva, oversees the financial operations and strategic planning for Teva's significant presence within Israel. This executive role involves managing all fiscal activities, including budgeting, financial reporting, and compliance, ensuring adherence to local regulations and corporate standards. Primovitch's responsibilities extend to optimizing financial performance and resource allocation within the Israeli market, supporting the company's commitment to delivering quality medicines. The Chief Financial Officer (Israel)'s leadership is crucial for navigating the specific economic landscape of Israel and contributing to Teva's overall financial stability and growth. Dov Primovitch's financial expertise ensures that local operations effectively support Teva's global mission of improving patient health outcomes by providing access to a broad portfolio of treatments. This function is essential for maintaining robust financial health in a key operational region.
Yehuda Koren - Director, Financial & Chief Financial Officer, S L E
Yehuda Koren, the Director, Financial & Chief Financial Officer, S L E at Teva, directs financial strategy and operations for specific business segments, indicated by 'S L E'. This executive role involves managing the financial health and performance of these designated areas, ensuring robust fiscal planning, budgeting, and reporting. Koren's responsibilities include optimizing financial resources and implementing controls to support Teva's mission of delivering a broad portfolio of medicines effectively. The Director, Financial & Chief Financial Officer, S L E's influence is critical in driving financial discipline and supporting strategic initiatives within these business units. Yehuda Koren's financial acumen contributes to Teva's overall objective of improving patient health outcomes by ensuring the efficient management of finances for key therapeutic solutions. This function is vital for maintaining financial integrity and supporting targeted business growth.
Eli Kalif - Chief Financial Officer & Executive VP
Eli Kalif, the Chief Financial Officer & Executive VP at Teva, leads the company's comprehensive financial strategy and execution on a global scale. This senior executive role involves overseeing all financial aspects, including financial planning, treasury, investor relations, and risk management, ensuring the fiscal integrity of Teva's worldwide operations. Kalif's leadership is pivotal in driving financial performance, optimizing capital structure, and supporting Teva's commitment to advancing scientific research and expanding access to quality medicines. The Chief Financial Officer & Executive VP's strategic direction guides investment decisions and resource allocation, crucial for the development and delivery of Teva's broad portfolio of treatments. Eli Kalif's financial stewardship is fundamental to achieving sustainable growth and enhancing shareholder value, directly contributing to Teva's mission of improving patient health outcomes globally. This executive function is essential for maintaining financial stability and driving strategic corporate initiatives.
Guillermo Monroy - LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy)
Guillermo Monroy, the LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy) at Teva, drives strategic growth initiatives across the Latin America region. This executive role focuses on identifying, evaluating, and executing mergers, acquisitions, and strategic partnerships that align with Teva's mission to improve global health outcomes. Monroy's responsibilities include developing comprehensive market entry strategies and assessing potential business opportunities to expand Teva's therapeutic offerings. The LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy)'s influence is critical in shaping the company's regional footprint and enhancing its competitive position. Guillermo Monroy's strategic acumen supports the expansion of Teva's broad portfolio, including complex generics and innovative therapies, ensuring greater access to quality medicines for patients in Latin America. This function is essential for driving inorganic growth and achieving long-term strategic objectives.
Alicia Logan - Chief of Staff & Senior Director, Commercial Excellence
Alicia Logan, the Chief of Staff & Senior Director, Commercial Excellence at Teva, enhances the effectiveness and efficiency of Teva's global commercial operations. This leadership position involves optimizing commercial strategies, driving best practices, and ensuring seamless execution across sales and marketing functions. Logan's responsibilities include fostering cross-functional collaboration and implementing initiatives that improve market access and patient engagement. The Chief of Staff & Senior Director, Commercial Excellence's focus on operational improvement directly supports Teva's mission to deliver a broad portfolio of medicines to patients worldwide. Alicia Logan's strategic guidance ensures that commercial teams are aligned with corporate objectives, driving sustainable growth and enhancing Teva's market presence. This role is vital for translating strategic vision into tangible commercial success and improving health outcomes through enhanced medicine delivery.
Hagay Leibowitz - Chief Marketing Officer, Project & Tgo, Teva Leader
Hagay Leibowitz, the Chief Marketing Officer, Project & Tgo, Teva Leader, directs marketing strategies and initiatives for key projects and the Tgo (Teva Global Operations) division. This executive role involves shaping market positioning, driving brand awareness, and developing go-to-market plans for Teva's diverse pharmaceutical offerings. Leibowitz's responsibilities include overseeing marketing campaigns, analyzing market trends, and identifying opportunities to enhance patient access to medicines. The Chief Marketing Officer, Project & Tgo, Teva Leader's focus on strategic marketing is crucial for supporting Teva's mission of improving health outcomes worldwide. Hagay Leibowitz's leadership ensures that marketing efforts align with corporate objectives, driving commercial success and reinforcing Teva's position as a global biopharmaceutical leader. This function is vital for effectively communicating the value of Teva's broad portfolio and advancing the company's strategic goals.
Explore Leadership Teams in Manufacturing
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries. The company is recognized as a world leader in blow-fill-seal technology, an advanced aseptic manufacturing process that forms, fills, and seals plastic containers in a continuous automated operation, ensuring high levels of sterility and product integrity. Unither's expertise encompasses the development and manufacturing of various liquid dosage forms including oral solutions, suspensions, nasal sprays, eye drops, and other sterile and non-sterile pharmaceutical products delivered in innovative single-dose formats. The company serves a diverse client base of pharmaceutical companies, biotechnology firms, and consumer health brands, providing comprehensive services from formulation development and clinical trial manufacturing to commercial-scale production and packaging. With manufacturing facilities strategically located across multiple continents including Europe and North America, Unither maintains strict quality standards and regulatory compliance with international pharmaceutical guidelines including FDA and EMA requirements. The company emphasizes innovation in drug delivery systems, patient convenience, and sustainability while helping clients bring their pharmaceutical products to market efficiently through its specialized manufacturing capabilities and technical expertise in unit-dose liquid formulations.
Company Leadership
ML
JK
GG
Amrutanjan Health Care Ltd specializes in pain and congestion management products, including aromatic balms, roll-ons, and sprays. Founded in 1893, the company is dedicated to enhancing people's well-being by combining natural extracts with scientific research to create effective, side-effect-free solutions. Their product range caters to various needs, including headache relief, body pain management, and women's hygiene. Amrutanjan aims to serve a global consumer base while maintaining a commitment to sustainability and social responsibility.
Company Leadership PD
MB
JC
Монос групп is a diversified company engaged in production, export, and import activities. They offer various services and manage projects while emphasizing social responsibility. The company also focuses on human resources, providing training and job opportunities. Their target clients include businesses and organizations seeking reliable partners in manufacturing and service sectors.
Company Leadership SK
MN
Frequently Asked Questions Regarding Teva Top Executives and Leadership Team
